Plain-English translation of NCT06257017 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
After surgery for muscle-invasive bladder cancer, some patients receive chemotherapy right away to reduce the chance of cancer returning. This trial is testing whether a new blood test that detects cancer cells circulating in your bloodstream can help doctors decide who truly needs early chemotherapy. The goal is to give the right treatment to the right patients at the right time.
Currently, doctors in Hong Kong don't routinely offer chemotherapy after bladder cancer surgery because of concerns about side effects. This new blood test could identify patients at highest risk of cancer returning, so chemotherapy is given only to those who really need it, sparing others from unnecessary treatment.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will have blood tests done to check for cancer cells circulating in your blood. Based on those results, you will be randomly assigned to one of two groups: one group receives chemotherapy immediately after surgery, while the other group is monitored and only receives chemotherapy if scans show cancer returning. You'll have regular clinic visits, blood tests, and imaging scans to monitor your progress over time.
AI-generated summary from trial data ยท Jun 7, 2026 ยท Not medical advice
Hong Kong